Camicinal clinical trials
Also written GSK962040.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses camicinal is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses camicinal is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With GastroparesisCompletedPhase 2GlaxoSmithKlineNCT01262898Written as GSK962040 (5 mg tablet)
- A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With GastroparesisCompletedPhase 2GlaxoSmithKlineNCT02210000Written as Camicinal
- Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE StudyTerminatedPhase 2GlaxoSmithKlineNCT01934192Written as GSK962040 50 mg
- A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040CompletedPhase 1GlaxoSmithKlineNCT00562848Written as GSK962040
- Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.CompletedPhase 1GlaxoSmithKlineNCT00733551Written as GSK962040
- GSK962040 Drug-drug Interaction Study With KetoconazoleCompletedPhase 1GlaxoSmithKlineNCT01039974Written as GSK962040
- A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric EmptyingCompletedPhase 2GlaxoSmithKlineNCT01602549Written as GSK962040 (25 mg tablet)
- The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With GastroparesisCompletedPhase 2GlaxoSmithKlineNCT00861809Written as GSK962040 25 mg
- Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed IntoleranceCompletedPhase 2GlaxoSmithKlineNCT01039805Written as GSK962040 (50 mg)
Codes
What other systems call camicinal · ClinicalTrials.gg INT005456
- UNII (FDA) 3C8348951HCAMICINALConfirmed FDA, Wikidata
- Wikidata Q27075653camicinalConfirmed FDA, Wikidata
- NCI Thesaurus C166668CamicinalOne source FDA
- DrugBank DB12567One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3C8348951H | CAMICINAL | Confirmed FDA, Wikidata |
| Wikidata | Q27075653 | camicinal | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166668 | Camicinal | One source FDA |
| DrugBank | DB12567 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.